

Role for a Phage Promoter in Shiga Toxin 2 Expression from a Pathogenic *Escherichia coli* Strain

PATRICK L. WAGNER,¹ MELODY N. NEELY,^{2†} XIAOPING ZHANG,¹ DAVID W. K. ACHESON,¹
MATTHEW K. WALDOR,^{1,3} AND DAVID I. FRIEDMAN^{2*}

Howard Hughes Medical Institute³ and Division of Geographic Medicine and Infectious Diseases, Tufts University School of Medicine, Boston, Massachusetts 02111¹; Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan 48109²

Received 1 November 2000/Accepted 3 January 2001

Shiga toxins (Stxs), encoded by the *stxA* and *stxB* genes, are important contributors to the virulence of *Escherichia coli* O157:H7 and other Stx-producing *E. coli* (STEC) strains. The *stxA* and *stxB* genes in STEC strains are located on the genomes of resident prophages of the λ family immediately downstream of the phage late promoters ($p_{R'}$). The phage-encoded Q proteins modify RNA polymerase initiating transcription at the cognate $p_{R'}$ promoter which creates transcription complexes that transcend a transcription terminator immediately downstream of $p_{R'}$ as well as terminator kilobases distal to $p_{R'}$. To test if this Q-directed processive transcription plays a role in *stx₂AB* expression, we constructed a mutant prophage in an O157:H7 clinical isolate from which $p_{R'}$ and part of Q were deleted but which has an intact p_{Stx} , the previously described *stx₂AB*-associated promoter. We report that production of significant levels of Stx2 in this O157:H7 isolate depends on the $p_{R'}$ promoter. Since transcription initiating at $p_{R'}$ ultimately requires activation of the phage lytic cascade, expression of *stx₂AB* in STEC depends primarily on prophage induction. By showing this central role for the prophage in *stx₂AB* expression, our findings contradict the prevailing assumption that phages serve merely as agents for virulence gene transfer.

Escherichia coli O157:H7 and other Shiga toxin (Stx)-producing *E. coli* (STEC) strains are responsible for outbreaks and sporadic cases of diarrhea. In some patients, exposure to STEC leads to hemorrhagic colitis and hemolytic uremic syndrome that may lead to death (20). Two major classes of Stxs, Stx1 and Stx2, encoded respectively by *stx₁AB* and *stx₂AB*, have been identified in STEC (2). The severe clinical consequences of STEC infections are thought to be caused by the activities of Stxs, although Stx2 appears to be more closely associated with these sequelae than does Stx1 (7, 28, 36). Shiga toxins are of the A-B type, with the glycolipid-binding B subunits being involved in the transport of the enzymatic A subunits into the eukaryotic cell where the A subunit, acting as a glycosylase, catalyzes a cleavage at a unique site in the 28S rRNA (2). The resulting inactivation of the ribosome leads to an inhibition of protein synthesis. More than 60 serotypes of STEC have been associated with human disease (1). The *stx* genes of many, if not all, STEC strains are in the genomes of prophages of the lambdoid family (19, 23, 27). This fact probably accounts for the wide dissemination of these genes in diverse *E. coli* serotypes.

Comparison of lambdoid phage genomes (9) has revealed a common arrangement of functionally similar genes and a shared strategy governing gene expression (Fig. 1). In the lysogenic state, the repressor silences transcription of most

phage genes (30). Removal of repression, which can occur when DNA damage activates the bacterial SOS response causing RecA-mediated cleavage of the repressor (21), leads to a cascade of regulatory events beginning with expression of the N transcription antitermination protein (30). Terminator read-through mediated by the N protein results in expression of delayed early genes that encode products involved in replication and prophage excision, as well as the Q antitermination protein (15). Q acts at a site, *qut*, within the phage late promoter, $p_{R'}$, modifying RNA polymerase to a highly processive form that reads through downstream terminators (39), including the strong Rho-independent terminator, $t_{R'}$, located directly downstream of $p_{R'}$ (32, 33). Thus, late gene expression by lambdoid prophages is a consequence of prophage induction; i.e., it follows removal of repression of the early promoters, $p_{R'}$ and p_L .

Although previous studies have identified functional promoters immediately upstream of *stx* genes (8, 34), recent evidence suggests that prophage induction and the resulting transcription from the phage $p_{R'}$ late promoters are likely to be important in *stx* expression (26). First, *stx* genes are located directly downstream of the $p_{R'}$ promoters and upstream of the phage lysis genes (25, 26, 29). Second, agents that induce Stx phages also increase Stx expression by their host STEC strains (24, 40). Third, the Q protein from Stx phage H-19B acting in *trans* directs high-level expression from the *stx* genes of repressed H-19B and 933W prophages, two phages that share nearly identical Q, *qut*, and $p_{R'}$ sequences but different *stx* genes (25, 29). Thus, these observations suggest that the regulatory circuits of Stx-encoding phages play a direct role in STEC pathogenesis. Moreover, if phage-directed lysis is important in Stx release from STEC cells, Q-activated transcrip-

* Corresponding author. Mailing address: Department of Microbiology and Immunology, Medical School, 5641 Medical Science Building II, University of Michigan, Ann Arbor, MI 48109-0620. Phone: (734) 763-3142. Fax: (734) 764-3562. E-mail: davidfri@umich.edu.

† Present address: Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.




FIG. 1. Presumed genome arrangement and transcription patterns of Stx2-encoding phage $\Phi 361$. This diagram is based on the maps of characterized lambdoid phages (16, 26), including the Stx2-encoding phage 933W (29), and the information we have on $\Phi 361$ (not drawn to scale). Shown are relevant genes, promoters, terminators, operators, and the site of the $\Delta Q-pR'$ deletion. The *attL* and *attR* sites are the junctions of the integrated prophage with the bacterial DNA. Below are shown the patterns of transcription initiating at the early promoters, *p_L* and *p_R*, in the absence and presence of N. Above are shown the patterns of transcription initiating at the late promoter *p_R'*, in the absence and presence of Q. Induction inactivates the repressor (*cI*), resulting in expression of the N protein-encoded antiterminator. N modification of RNA polymerase allows read-through of the *t_{L1}* and *t_{R1}* terminators, resulting in production of proteins catalyzing excision and replication of the phage genome. The N-modified RNA polymerase also reads through the *t_{R2,3,4}* terminators, leading to synthesis of the Q antiterminator. The Q-modified RNA polymerase transcends transcription termination at *t_R'* and subsequent downstream terminators, allowing expression of late genes, which include those encoding proteins involved in lysis and morphogenesis. *Recomb.*, recombination; *Rep.*, replication.

tion of *stx* and downstream lysis genes may serve as the primary mechanism for coordinating production and release of toxin during a STEC infection (26, 38). We present evidence that transcription from the late phage promoter *p_R'*, resulting from prophage induction plays a major role in the production of toxin from the Stx2-encoding O157:H7 enterohemorrhagic *E. coli* clinical isolate 1:361.

MATERIALS AND METHODS

Bacteria and plasmids. Strain 1:361, a clinical *E. coli* isolate of serotype O157:H7, has previously been described (37). Strain 1:361 $\Delta Q-pR'$ was derived from 1:361 using the allele exchange vector p $\Delta Q-pR'$. This plasmid is a derivative of the *sacB* counterselectable vector pCVD442 (13), which contains an ~900-bp DNA fragment from the *p_R'* region of $\Phi 361$ with a 189-bp deletion that includes *p_R'*. The inserted fragment was synthesized using the procedure involving PCR-based splicing by overlap extension (18) with the 1:361 chromosomal DNA serving as the template. Four primers were employed in constructing this fragment: the upstream primer 5'CACGTA AAAACCATTCCTGACATGCTCC, corresponding to sequences in the Q gene; the overlapping primers 5'CCTTTC TGTGTACTTTCGCCAGCATCATCAGCATGCC and 5'GGCATGCTGAT GATGCTGGCGGAAAGTACACAGAAAGG, corresponding to sequences upstream and downstream of the deleted region; and 5'GCCACCACATTAAC TGAAAGATAAC, corresponding to sequences downstream of *p_R'*. p $\Delta Q-pR'$ was introduced into 1:361 by conjugation with *E. coli* strain SM10 λ pir. Exconjugates were selected as streptomycin- and ampicillin-resistant colonies. Haploid cells were then selected as sucrose-resistant colonies as described previously (13) and subsequently screened for $\Delta Q-pR'$ mutations. DNA sequence analysis confirmed that 1:361 $\Delta Q-pR'$ contains the proper deletion.

RNA preparation. RNA from mid-log-phase culture of 1:361 or 1:361 $\Delta Q-pR'$ was prepared using an RNeasy kit (Qiagen). Northern blotting was performed using standard procedures (3) with a ³²P-labeled *stx_{2A}* riboprobe. The *stx_{2A}* probe was synthesized using T7 polymerase (Ambion), with plasmid pPW58 (which contains 258 bp of *stx_{2A}* coding sequence subcloned into plasmid pCR2.1-TOPO [Invitrogen]) as the template.

Animal model. A modified version of the streptomycin-treated-mouse model of enterohemorrhagic *E. coli* infection (35) was used to compare the levels of colonization and intestinal Stx2 production of 1:361 and 1:361 $\Delta Q-pR'$. Four-week-old CD-1 mice were given drinking water containing streptomycin (2 g/liter) throughout each experiment. Two days after streptomycin treatment was begun, mice were inoculated intragastrically with ~10¹⁰ CFU of either 1:361 or 1:361 $\Delta Q-pR'$. Fecal samples were collected daily beginning 1 day after inoculation. Numbers of streptomycin-resistant CFU of either 1:361 or 1:361 $\Delta Q-pR'$ and fecal Stx2 concentration were determined as described previously (41).

Toxin assay. Stx levels were measured using an enzyme-linked immunosorbent assay (ELISA) essentially as previously described (14).

RESULTS

Prophage construction. *E. coli* strain 1:361, isolated from a patient with bloody diarrhea, contains two Stx2-encoding lambdoid prophages (data not shown). One of these phages was found to be defective, and the other, designated $\Phi 361$, shares, at a minimum, the *Q*, *p_R'*, and *stx₂* sequences found in phage 933W (37) (Fig. 1). We constructed a derivative of 1:361, called 1:361 $\Delta Q-pR'$, in which a 189-bp region including the 3' end of *Q* and the *p_R'* late promoter of the $\Phi 361$ prophage was deleted (Fig. 1). This deletion left intact the *stx_{2A}* and *-B* genes and the previously identified *stx₂* promoter, *pStx2*. As expected for a lysogen carrying a lambdoid prophage defective in transcription from *p_R'*, 1:361 $\Delta Q-pR'$ did not produce phage detectable by plaque formation following induction with mitomycin C (Fig. 2C).

Transcription levels. Northern blotting was performed to directly assess the role of transcription initiating at *p_R'* in *stx* expression (Fig. 2A). Strain 1:361 produced low levels of the *stx* transcript (lane 1), while strain 1:361 $\Delta Q-pR'$ (lane 3) failed to produce detectable levels of the *stx* transcript. Following induction with mitomycin C, strain 1:361 produced high levels of the *stx* transcript (lane 2), while strain 1:361 $\Delta Q-pR'$ again failed to produce observable levels of the *stx* transcript (lane 4). Based on studies with λ (33), Q-mediated antitermination of transcription initiating at *p_R'* is expected to result in a >25-kb message; however, the relatively small size of the *stx* transcript is not surprising for an mRNA initiating at *p_R'* since the λ *p_R'* message is known to be processed (11). Therefore, these experiments provide evidence that the *Q-p_R'* region in $\Phi 361$, which is necessary for transcription of late phage genes, is also important for *stx₂* transcription.

Toxin levels. Stx levels in cultures of 1:361 and 1:361 $\Delta Q-pR'$, measured by an ELISA (14), provide further evidence that transcription from *p_R'* contributes significantly to *stx* expression (Fig. 2B). Uninduced cultures of strain 1:361 produced low levels of Stx2, and under identical conditions, cultures of 1:361 $\Delta Q-pR'$ failed to produce measurable levels of Stx2. Thus, the low level of Stx produced by the untreated culture most

Treatment/ Product Measured	Bacteria			
	1:361		$\Delta Q-p_R'$	
	1	2	3	4
Mitomycin C	-	+	-	+
A RNA Northern Blot				
B Stx2 (ng/ml)	9.0 +/- 1.4	167.3 +/- 18.0	<0.1	9.2 +/- 0.8
C Phage Titer (pfu/ml)	2.1×10^4	2.0×10^9	0	2×10^4

FIG. 2. Production of *stx*₂ RNA, Stx2, and phage from STEC strains 1:361 and 1:361 $\Delta Q-p_R'$. (A) Measurement by Northern blotting of *stx* mRNA levels. Total RNA was prepared from 3-h cultures of 1:361 and 1:361 $\Delta Q-p_R'$ grown with (+) or without (-) 0.5 μ g of mitomycin C per ml. Six micrograms of RNA was run on a 1% agarose gel, transferred to a nylon membrane, and then probed with a ³²P-labeled Stx2-encoding sequence riboprobe. (B) Total Stx2 was measured from the same cultures used in the Northern blot, using a previously described ELISA (14). Values with standard deviations from three independent measurements are shown. (C) Phage titers were determined using *E. coli* C600 as the indicator strain (3). This procedure leaves uncounted mutant phage producing very low bursts.

likely resulted from Q-stimulated transcription from $p_{R'}$ in the small fraction of lysogens in which there was spontaneous induction of the prophage. Induced cultures of 1:361 (treated with mitomycin C) produced high levels of Stx2, while similarly treated cultures of 1:361 $\Delta Q-p_R'$ produced toxin levels that were nearly 20-fold less (Fig. 2B). These results confirm the conclusion from the Northern analysis that the $Q-p_{R'}$ region exerts a critical role in regulating Stx2 synthesis in vitro.

Stx production in vivo. To assess the physiological relevance of these findings, Stx2 production by strains 1:361 and 1:361 $\Delta Q-p_R'$ was examined in vivo, using a mouse model system (35). In these experiments, CD-1 mice were inoculated intragastrically with either 1:361 or 1:361 $\Delta Q-p_R'$. Over the course of 4 days, stool samples were collected and assayed both for CFU of 1:361 or 1:361 $\Delta Q-p_R'$ and for levels of Stx2. In striking contrast to the similar numbers of 1:361 and 1:361 $\Delta Q-p_R'$, CFU recovered, the difference in the amounts of Stx in the stool specimens between the mice inoculated with the two strains was dramatic (Fig. 3). There was an approximately 30-fold lower concentration of Stx2 in stools from animals inoculated with 1:361 $\Delta Q-p_R'$ than the concentration of Stx2 in stools from mice inoculated with 1:361. Thus, Stx production by strain 1:361 in the animal gut, as in vitro culture, largely derives from the small fraction of the bacteria in which there is prophage induction.

DISCUSSION

Previous studies identified a functional promoter, p_{Stx} , immediately upstream of *stx* genes in the Stx1-encoding phage H-19B (8) and the Stx2-encoding phage 933W (34). These findings appeared to confirm the idea that, although *stx* genes

can be carried by phages, once the phage is established as a prophage, *stx* is expressed independently of the regulatory system governing phage gene expression. More recent studies led to the suggestion that phage-encoded regulatory circuits that result in Q modification of transcription initiating at the phage $p_{R'}$ promoter and subsequent processive transcription of downstream genes, including *stxA* and *stxB*, may play a role in *stxAB* expression (26). We directly tested this hypothesis by deleting the $Q-p_{R'}$ region while leaving intact the p_{Stx} promoter of a prophage that carries the *stx*_{2A} and *stx*_{2B} genes in an *E. coli* O157:H7 clinical isolate.

Our experiments comparing levels of Stx2 production by the parent clinical strain and an isogenic derivative with a deletion of the $Q-p_{R'}$ region of the prophage provide compelling evidence supporting the idea that Q-activated $p_{R'}$ -promoted processive transcription plays a critical role in Stx2 production. Since Q expression depends on transcription from $p_{R'}$, a promoter that is under repressor control, *stx* expression, according to this idea, ultimately depends on induction of the prophage. Induction is expected to result in increased *stx* copy number and increased transcription of phage late genes initiating from the early promoter $p_{R'}$. However, copy number and increased transcription of phage late genes by N-antiterminated transcription from the early promoter $p_{R'}$ are not expected to be affected by the $\Delta Q-p_{R'}$ deletion (17). Therefore, our results strongly suggest that high-level Q-modified transcription initiating at the $\Phi 361$ $p_{R'}$ late promoter is responsible for the increase in Stx2 production observed upon induction of strain 1:361. Residual toxin production by 1:361 $\Delta Q-p_{R'}$ may be due




FIG. 3. Fecal cell counts of 1:361 and 1:361 $\Delta Q-p_{R'}$ and Stx2 concentration. Streptomycin-treated CD-1 mice were intragastrically inoculated with either 1:361 or 1:361 $\Delta Q-p_{R'}$. Stool samples were collected daily, and the Stx2 concentration (top) and the number of CFU (bottom) of either 1:361 or 1:361 $\Delta Q-p_{R'}$ were determined. Gray bars represent mice inoculated with 1:361, and black bars represent mice inoculated with 1:361 $\Delta Q-p_{R'}$. There were eight mice in each group. Means and standard deviations are presented.

to low-level transcription from the early $p_{R'}$ promoter (10) or p_{Stx2} and possibly from the other defective $Stx2$ -encoding phage present in 1:361. Our results are consistent with the hypothesis that Q-modified transcription (32) beginning at $p_{R'}$ proceeds through the terminator $t_{R'}$, into the stx genes, past termination signals, and through the downstream lysis genes, providing a unified mechanism for coupling Stx production and release. Previously, Stx phages were considered to be important in the dissemination of but not the regulation of expression of toxin genes (38). Our results favor the view that stx_2 expression is regulated as one of the late phage genes and suggest that, far from being a mere vector for toxin gene transfer, $\Phi 361$ directs production of $Stx2$ as part of its lytic cycle. If our model is correct, it would mean that an induced subpopulation of the total infecting STEC population is responsible for significant levels of Stx production. This does not appear to be the exclusive mode for regulating virulence gene expression in lambdoid phages. The prototypical λ itself encodes *bor* and *lom*, genes encoding proteins having significant homology to known bacterial virulence factors (5) and, in the case of *bor*, shown to confer a virulence phenotype (6). The biologically relevant expression of these genes, unlike that of the stx genes, occurs from the repressed prophage.

Our study raises a question about the evolution of stx -carrying phages. Since the subpopulation of bacteria postulated to be the primary producers of Stx would not survive to be infectious, how can evolution select for stx if its production is coupled with phage-mediated lysis? The diarrhea induced by Stx likely contributes to the dissemination of the remaining population, an effect that may outweigh selection against toxin producers. There is precedence for the idea that the death of a minority of a bacterial population contributes to the survival advantage of the majority. Bacteriocins, molecules produced by some bacteria that are lethal to other bacteria of the same and closely related species, are produced by a subpopulation that is lysed in the process of releasing the bacteriocin (31). A possible role for the phage in expression of phage-borne virulence genes has been considered since the early demonstration that diphtheria toxin is carried by a phage (4). As far as we know, the results of our study provide the first evidence directly linking a phage regulatory cascade with expression of a phage-encoded virulence factor.

Expression of virulence factors, even when carried by mobile genetic elements, is generally considered in the context of overall coordination of the infectious strategy of the host bacterium (22). Here we present evidence that the bacteriophage life cycle is the dominant, if not the only, important factor involved in $Stx2$ expression. It will be interesting to learn whether phage control of virulence gene expression is unique to stx or can serve as a paradigm that explains regulation of expression of other phage-encoded virulence factors. In light of our findings, an understanding of the conditions in the intestine that trigger prophage induction and subsequent up-regulation of Stx expression takes on new significance. Notable pharmacologic agents which induce prophages include mitomycin C, used in chemotherapy, and numerous antibiotics, including the fluoroquinolones, often used in treatment of diarrhea (41). Interestingly, endogenous products of inflammatory cells, such as H_2O_2 , are also known to induce lambdoid prophages (12). While it remains unknown to what extent such

exogenous and endogenous factors contribute to STEC pathogenesis, our study suggests that clinical intervention to prevent prophage induction may reduce Stx production during STEC infection.

ACKNOWLEDGMENTS

P.L.W. and M.N.N. contributed equally to this work. We thank Andrew Camilli, Victor DiRita, Michelle Swanson, and Bridgid Davis for critical reading of the manuscript. Eric Olson is thanked for helpful discussions and encouragement.

This work was supported by grants from the NIH (D.I.F., M.K.W., and D.W.K.A.), the Pew Foundation (M.K.W.), the FDA (D.W.K.A.), the HHMI (P.L.W. and M.K.W.), and an NIH biotechnology training grant (M.N.N.).

REFERENCES

- Acheson, D. W. K., and G. T. K. Keusch. 1996. Which Shiga toxin-producing types of *Escherichia coli* are important? *ASM News* **62**:302–306.
- Acheson, W. K., A. Donohue-Rolfe, and G. T. Keusch. 1991. The family of Shiga and Shiga-like toxins, p. 415–433. *In* J. E. Alouf and J. H. Freer (ed.), *Sourcebook of bacterial protein toxins*. Academic Press, London, United Kingdom.
- Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1999. *Current protocols in molecular biology*. John Wiley & Sons, Inc., New York, N.Y.
- Barksdale, L., and S. B. Arden. 1974. Persisting bacteriophage infections, lysogeny, and phage conversion. *Annu. Rev. Microbiol.* **28**:265–297.
- Barondess, J. J., and J. Beckwith. 1990. A bacterial virulence determinant encoded by lysogenic coliphage lambda. *Nature* **346**:871–874.
- Barondess, J. J., and J. Beckwith. 1995. *bor* gene of phage lambda, involved in serum resistance, encodes a widely conserved outer membrane lipoprotein. *J. Bacteriol.* **177**:1247–1253.
- Boerlin, P., S. A. McEwen, F. Boerlin-Petzold, J. B. Wilson, R. P. Johnson, and C. L. Gyles. 1999. Associations between virulence factors of Shiga toxin-producing *Escherichia coli* and disease in humans. *J. Clin. Microbiol.* **37**:497–503.
- Calderwood, S. B., F. Auclair, A. Donohue-Rolfe, G. T. Keusch, and J. J. Mekalanos. 1987. Nucleotide sequence of the Shiga-like toxin genes of *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **84**:4364–4368.
- Campbell, A. 1994. Comparative molecular biology of lambdoid phages. *Annu. Rev. Microbiol.* **48**:193–222.
- Dambly, C., and M. Couturier. 1971. A minor Q-independent pathway for expression of late genes in bacteriophage lambda. *Mol. Gen. Genet.* **113**:244–250.
- Daniels, D. L., M. N. Subbarao, F. R. Blattner, and H. A. Lozeron. 1988. Q-mediated late gene transcription of bacteriophage lambda: RNA start point and RNase III processing sites in vivo. *Virology* **167**:568–577.
- DeMarini, D. M., and H. G. Brooks. 1992. Induction of prophage lambda by chlorinated organics: detection of some single-species/single-site carcinogens. *Environ. Mol. Mutagen.* **19**:98–111.
- Donnenberg, M. S., and J. B. Kaper. 1991. Construction of an *eaec* deletion mutant of enteropathogenic *Escherichia coli* by using a positive-selection suicide vector. *Infect. Immun.* **59**:4310–4317.
- Donohue-Rolfe, A., D. W. Acheson, A. V. Kane, and G. T. Keusch. 1989. Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. *Infect. Immun.* **57**:3888–3893.
- Friedman, D. I., and D. L. Court. 1995. Transcription antitermination: the lambda paradigm updated. *Mol. Microbiol.* **18**:191–200.
- Hendrix, R. W., J. W. Roberts, F. W. Stahl, and R. A. Weisberg. 1983. Lambda II. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- Herskowitz, I., and Signer. 1970. Control of transcription from the r strand of bacteriophage lambda. *Cold Spring Harbor Symp. Quant. Biol.* **35**:355–368.
- Horton, R. M., Z. L. Cai, S. N. Ho, and L. R. Pease. 1990. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. *BioTechniques* **8**:528–535.
- Huang, A., J. Friesen, and J. L. Brunton. 1987. Characterization of a bacteriophage that carries the genes for production of Shiga-like toxin I in *Escherichia coli*. *J. Bacteriol.* **169**:4308–4312.
- Kaper, J. B., and A. D. O'Brien. 1998. *Escherichia coli* O157:H7 and other Shiga toxin-producing *E. coli* strains. American Society for Microbiology, Washington, D.C.
- Little, J. W. The SOS regulatory system, p. 453–479. *In* E. C. C. Linn and A. S. Lynch (ed.), *Regulation of gene expression in Escherichia coli*. R. G. Landis Co., Georgetown, Tex.
- Mekalanos, J. J. 1992. Environmental signals controlling expression of virulence determinants in bacteria. *J. Bacteriol.* **174**:1–7.

23. Mizutani, S., N. Nakazono, and Y. Sugino. 1999. The so-called chromosomal verotoxin genes are actually carried by defective prophages. *DNA Res.* **6**:141–143.
24. Mühlendorfer, I., J. Hacker, G. T. Keusch, D. W. Acheson, H. Tschape, A. V. Kane, A. Ritter, T. Olschlager, and A. Donohue-Rolfe. 1996. Regulation of the Shiga-like toxin II operon in *Escherichia coli*. *Infect. Immun.* **64**:495–502.
25. Neely, M. N., and D. I. Friedman. 1998. Arrangement and functional identification of genes in the regulatory region of lambdoid phage H-19B, a carrier of a Shiga-like toxin. *Gene* **223**:105–113.
26. Neely, M. N., and D. I. Friedman. 1998. Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. *Mol. Microbiol.* **28**:1255–1267.
27. O'Brien, A. D., J. W. Newland, S. F. Miller, R. K. Holmes, H. W. Smith, and S. B. Formal. 1984. Shiga-like toxin-converting phages from *Escherichia coli* strains that cause hemorrhagic colitis or infantile diarrhea. *Science* **226**:694–696.
28. Ostroff, S. M., P. I. Tarr, M. A. Neill, J. H. Lewis, N. Hargrett-Bean, and J. M. Kobayashi. 1989. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in *Escherichia coli* O157:H7 infections. *J. Infect. Dis.* **160**:994–998.
29. Plunkett, G., III, D. J. Rose, T. J. Durfee, and F. R. Blattner. 1999. Sequence of Shiga toxin 2 phage 933W from *Escherichia coli* O157:H7: Shiga toxin as a phage late-gene product. *J. Bacteriol.* **181**:1767–1778.
30. Ptashne, M. 1992. A genetic switch, 2nd ed. Cell Press, Blackwell Scientific Publications, Cambridge, Mass.
31. Riley, M. A. 1998. Molecular mechanisms of bacteriocin evolution. *Annu. Rev. Genet.* **32**:255–278.
32. Roberts, J. 1992. Antitermination and the control of transcription elongation, p. 389–406. *In* S. L. McKnight and K. R. Yamamoto (ed.), *Transcription regulation*. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
33. Roberts, J. W., W. Yarnell, E. Bartlett, J. Guo, M. Marr, D. C. Ko, H. Sun, and C. W. Roberts. 1998. Antitermination by bacteriophage Lambda Q protein. *Cold Spring Harbor Symp. Quant. Biol.* **63**:319–325.
34. Sung, L. M., M. P. Jackson, A. D. O'Brien, and R. K. Holmes. 1990. Transcription of the Shiga-like toxin type II and Shiga-like toxin type II variant operons of *Escherichia coli*. *J. Bacteriol.* **172**:6386–6395.
35. Wadolkowski, E. A., J. A. Burris, and A. D. O'Brien. 1990. Mouse model for colonization and disease caused by enterohemorrhagic *Escherichia coli* O157:H7. *Infect. Immun.* **58**:2438–2445.
36. Wadolkowski, E. A., L. M. Sung, J. A. Burris, J. E. Samuel, and A. D. O'Brien. 1990. Acute renal tubular necrosis and death of mice orally infected with *Escherichia coli* strains that produce Shiga-like toxin type II. *Infect. Immun.* **58**:3959–3965.
37. Wagner, P. L., D. W. Acheson, and M. K. Waldor. 1999. Isogenic lysogens of diverse Shiga toxin 2-encoding bacteriophages produce markedly different amounts of Shiga toxin. *Infect. Immun.* **67**:6710–6714.
38. Waldor, M. K. 1998. Bacteriophage biology and bacterial virulence. *Trends Microbiol.* **6**:295–297.
39. Yarnell, W. S., and J. W. Roberts. 1999. Mechanism of intrinsic transcription termination and antitermination. *Science* **284**:611–615.
40. Yee, A. J., S. De Grandis, and C. L. Gyles. 1993. Mitomycin-induced synthesis of a Shiga-like toxin from enteropathogenic *Escherichia coli* H.I.8. *Infect. Immun.* **61**:4510–4513.
41. Zhang, X., A. D. McDaniel, L. E. Wolf, G. T. Keusch, M. K. Waldor, and D. W. Acheson. 2000. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. *J. Infect. Dis.* **181**:664–670.